Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
Public ClinicalTrials.gov record NCT01418352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Study identification
- NCT ID
- NCT01418352
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Aripiprazole Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 7 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2011
- Primary completion
- Mar 11, 2014
- Completion
- Mar 11, 2014
- Last update posted
- Oct 6, 2021
2011 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Dothan | Alabama | 36303 | — |
| Not listed | San Francisco | California | 94143 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Miami | Florida | 33126 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Atlanta | Georgia | 30329 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Omaha | Nebraska | 68131 | — |
| Not listed | Manhasset | New York | 11030 | — |
| Not listed | Cincinnati | Ohio | 45229-3039 | — |
| Not listed | Oklahoma City | Oklahoma | 73112 | — |
| Not listed | Charlottesville | Virginia | 22903 | — |
| Not listed | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01418352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01418352 live on ClinicalTrials.gov.